The Cholesterol War Is Over (Here's Who Won)

0:00 In 2006, researchers in Dallas found a woman who broke everything that we thought we knew about cholesterol. She was 32 years old, a healthy aerobics instructor, normal liver, normal kidneys, no health problems. But then when they tested her blood, her LDL cholesterol came back at 14, not 140, 14. To put that into perspective, the average LDL cholesterol in a healthy adult is around 100 to 130 mg per deciliter, and doctors generally start to get a bit concerned if the levels go above 160. Below 70 is considered excellent for high-risk patients. But this woman was at 14. So how was that possible? Well, Helen Hobbs wanted to find out, and the irony is she hadn't planned on studying cholesterol. When her mentor at UT Southwestern suggested that she joined a lipid research lab, her reaction was immediate.

0:48 Lipoproteins, oh no, so boring. And she later admitted that that just tells you how little I understood about science. So she and Jonathan Cohen had been running a massive project called the Dallas Heart Study, collecting DNA from thousands of residents, linking it to their medical records to see what patterns emerged. Now in some people, they noticed astonishingly low LDL cholesterol levels. And when they checked the DNA, they found mutations in a gene called PCSK9. But these mutations, they weren't making the gene overactive, they were shutting it down.

1:20 And the people who carried these mutations, they weren't getting sick, they were thriving. They had dramatically lower rates of heart disease, about an 88% reduction in coronary heart disease risk. So that aerobics instructor, she had mutations in both copies of her PCSK9 gene. So her body produced none of that protein, and she was perfectly healthy. So what Hobbs had stumbled upon was the clearest natural experiment in cardiovascular medicine. If you could block PCSK9, you could dramatically lower your LDL cholesterol safely. So now the race was on to build a drug that could mimic what this woman's DNA was naturally doing.

1:56 And Hobbs later described how fast the field moved. So geneticists, they took a little while to understand this, but the pharmaceutical companies, they got it right away. So what does PCSK9 actually do? Well, in simple terms, it destroys the receptors on your liver that your liver uses to pull LDL particles out of your blood. So the more PCSK9 that you have, the fewer receptors that survive, and the higher your LDL particles in your blood climbs. So if you block PCSK9, those receptors survive and more cholesterol particles get cleared. And it was Amgen who designed a drug called evolocumab, which is a protein that latches onto circulating PCSK9 and neutralizes it before it can destroy the LDL receptors. And in early trials, LDL cholesterol, it dropped by 81% on top of statin therapy. So for patients who struggled with high cholesterol despite maximum statin doses, this was a completely new tool. But lowering a number on a blood test is not the same as preventing heart attacks. That requires a much bigger, much longer, and much more expensive study. So the FOURIER trial was that study. It involved over 27,000 patients with existing heart disease. So half of them received evolocumab, and the other half received a placebo, all on top of statin therapy. And the result is a 20% reduction in heart attacks, strokes, and cardiovascular deaths. That was a triumph, but it came with a caveat that critics were quick to point out. Every patient in the FOURIER study had already had established heart disease. So skeptics argued that aggressive LDL lowering might only help people who were already in trouble. Maybe pushing cholesterol that low in healthier patients would cause more harm than good. So the harder question was this: What if you started earlier? Could you prevent the first heart attack, not just the second or third? So in a follow-up study called the VESALIUS CV trial, researchers looked at over 12,000 patients across 33 countries. None of these patients had ever had a heart attack or a stroke. All of them had pre-existing atherosclerosis, which basically just means that they had pre-existing blockages in their blood vessels, or they were high-risk diabetics with LDL cholesterol levels of at least 90 mg per deciliter. And after the 4.6-year follow-up study period, roughly twice as long as the FOURIER study, the answer came back as yes.

4:11 There was a 25% reduction in heart attacks, strokes, and cardiovascular disease. So it had taken 20 years, but what Helen Hobbs had found in that aerobics instructor's blood had been validated in the largest scale imaginable. Ultra-low LDL was not dangerous, it was protective. And now we had proof that deliberately lowering it before a heart attack ever happens could prevent that heart attack from ever occurring. But the VESALIUS CV study, it included a mix of patients. So some of them had existing atherosclerosis again, plaque buildup in their blood vessels, but some other patients had just diabetes with no visible disease. So the question was whether the benefit held up in that second group. So the ones further back in the disease process that hadn't yet developed plaque in their blood vessels, the ones that most doctors wouldn't think to treat aggressively. Well, the question was answered on March 28th, 2026 at the American College of Cardiology conference. So researchers, they presented a pre-specified analysis of just the diabetic patients in the VESALIUS CV study. So this was a group of just over 3,000 people with diabetes, but again they'd never had a heart attack, they'd never had a stroke, and they had no significant atherosclerosis.

5:20 So half of them received evolocumab, and the other half received a placebo. And again, they were followed up for about 4.8 years. And at the 48-week mark, the LDL cholesterol in the treatment group, it dropped to 52 mg per deciliter compared to 110 mg per deciliter in the placebo group. And by the 98-week mark, the median was down to 44 mg per deciliter. And the clinical impact was striking. The combination of heart attacks, strokes, and cardiovascular death was reduced by, and get this, 31%.

5:52 5% in the evolocumab group versus 7.1% in the placebo group. So a hazard ratio of 0.69. And then there were the exploratory findings that stopped me in my tracks. A signal for reduced all-cause mortality. There was a 24% lower risk of dying from any cause. Now this is a subgroup analysis, and mortality was not as pre-specified outcome, so we can't make definitive claims here. But a hazard ratio of 0.76 for all-cause mortality in a primary prevention population is a signal that you do need to take seriously. And one detail that matters here, the benefit emerged after the first year. And this makes sense. By stopping plaque from developing in the first place, it's going to be a slow, steady accumulation of protection. Dr. Nicholas Masston, who is one of the study authors, put it directly, "I think the study changes the paradigm. We don't have to wait until someone has atherosclerosis to treat them intensively. It challenges the way that most doctors think about cholesterol treatment, waiting for the disease to declare itself before getting too aggressive. The starter suggests that waiting costs lives." But here's the problem. Evolocumab is an injection.

7:00 It costs thousands of dollars per year. And even for patients with established heart disease, insurance companies, they often reject the majority of prescriptions. And for diabetic patients with no prior events, good luck trying to get an approval. So the VESALIUS CV subgroup analysis, it gives us the science, but for most patients, if they want to achieve these aggressive LDL targets, it means that we should opt for using cheap, off-patent drugs that are readily available. So statins and ezetimibe, for instance. And until very recently, no one had actually tested whether aiming for specific lower numbers made a difference. But consider this case. A 53-year-old woman, total cholesterol of 141, LDL of 67, non-smoker, no family history, normal blood pressure. By every guideline, she was at target. But she had four blocked arteries and needed open-heart surgery.

7:51 Her friend's reaction afterwards said, "I thought you could only get heart disease if you had high cholesterol." Her case likely involved other risk factors beyond LDL. But the point here stands. An LDL of 67 gave her and her doctor false reassurance. And she's not an isolated case. A study of nearly 137,000 heart attack hospitalizations found that almost 75% of patients had cholesterol levels within the recommended targets. Nearly one in five had an LDL of below 70, that supposed goal. So the question becomes, if the target of 70 isn't low enough, what should it be? And that brings us to the second study that was published at the American College of Cardiology conference in 2026. So in some ways, it might be even more important than that VESALIUS CV study that we looked at earlier. So the new trial that we're going to look at is called the ISCEV study, and it's the first randomized clinical trial to directly compare two specific LDL cholesterol targets head-to-head. So one group aimed for below 55 mg per deciliter versus the standard 70 mg per deciliter. The study enrolled 3,048 patients with established cardiovascular disease across 17 centers in South Korea, and they were followed up for 3 years. In the intensive group, the median LDL achieved was 56 mg per deciliter, and in the standard group, it was 66 mg per deciliter. But the results were clear. The primary outcome of the study, which was a combination of cardiovascular deaths, heart attacks, strokes, revascularization, or hospitalization for unstable angina, occurred in 6.6% in the intensive group versus 9.7% in the standard group.

9:32 That's a 33% relative risk reduction. The difference between an LDL of 56 compared to an LDL of 66 is just 10 mg per deciliter, but that translated to a third fewer major events. The individual outcomes were even more striking. Non-fatal heart attacks were more than halved with a hazard ratio of 0.46. Any revascularization, the hazard ratio was 0.63. So what about safety? Well, there were no signals of harm. There was no excess diabetes, no myopathy, no liver toxicity. Dr. Christopher Cannon, who commented on the trial, he put it simply, "55 is our new goal, and we need to really embrace that and work hard to get patients to that new goal." All of this aligns with the low target that I've personally aimed for over the past few years, and I base that on a study called the PESA study. It imaged the arteries of 4,184 apparently healthy middle-aged adults with no cardiovascular disease. What they found in a subgroup analysis of those with no conventional cardiovascular risk factors, so no high blood pressure, no obesity, no insulin resistance, etc., was striking. Nearly half had already developed plaque in their blood vessels, and when they looked at the relationship between LDL cholesterol levels and plaque burden, the data showed a clear linear pattern, and the chart from the study is worth seeing. So, the plaque built up even if LDL cholesterol was at 60, and it climbed to 64% in those with LDL of between 150 to 160. And critically, the authors note that plaque buildup appears to only develop at an LDL threshold of approximately 50 to 60 mg per deciliter, the very range that the new high-risk guidelines are now targeting. And the free health roadmap tool that I've created takes into account this PESA data, and you can find a link in the pinned comment to try it out. Now, I should note some important limitations. The ESPRIT study that compared the older target of 70 with the more aggressive target of 55 was conducted entirely in South Korea. So, ideally, we'd want to see this replicated in other populations, and only 60.8% of patients in the intensive arm actually achieved the target of below 55 at the 3-year mark. But the implication here is still powerful.

11:45 Every point of LDL cholesterol matters, and the old target of 70 can leave significant benefits on the table, and the PESA study tells us the same thing. And here's the part of the story that really frustrates me as a doctor. So, the drug that the ESPRIT study used to help patients get from 66 mg per deciliter down to 56 mg per deciliter, it wasn't some cutting-edge injectable that costs thousands of dollars a year. Instead, the drug is called ezetimibe, and ezetimibe is cheap, it's off-patent, and it works by basically telling your gut to not absorb as much cholesterol.

12:18 It's generic, it costs almost nothing, and as of the most recent data, only 6% of patients with established cardiovascular disease are taking it. 6%. Karen Aspry, who's a cardiologist at Brown University, called the ESPRIT study a real-world approach for how clinicians should be titrating to a lower target using ezetimibe, which many are not doing. 2/3 of heart disease patients aren't at the LDL cholesterol target despite using statins. So, there's a cheap generic pill that could help most of them get there, but almost nobody is prescribing it. So, for my patients, we have an open discussion about aiming for the more aggressive 55 target rather than 70. And personally, I take a statin as well as ezetimibe. And for the group of patients who can't reach their target levels despite using statins and ezetimibe, PCSK9 inhibitors, they do remain an option, though at the moment, cost is still a barrier. But there's reason for optimism here, too. A new oral PCSK9 inhibitor recently showed a 58% LDL reduction in a phase 3 trial.

13:19 So, when it's approved, it could remove the injection barrier entirely. And the earlier you start lowering your LDL cholesterol levels, the more benefit you'll get. Now, there are some other dietary components that do have effectiveness in lowering LDL cholesterol. So, soluble fiber is one of them, and that's why I included psyllium husk, a well-studied source of soluble fiber with cholesterol-lowering effects in multivitamin plus powder. But just because I take a supplement does not in any way mean that you should as well.

13:46 Now, coming back to that woman in Dallas, the aerobics instructor with an LDL of 14, and Helen Hobbs who looked at her blood and saw something that most scientists would have dismissed, it launched a 20-year chain of discoveries. The gene, the drug, the trials, and now for the first time, head-to-head evidence for that exact number to aim for. The science is clear, lower is better, the earlier the better, and the target that your doctor was likely trained on is probably too high. The only question left is whether we should act on it. And something that unfortunately has muddied the waters here is a controversy over whether there's an important link between our cholesterol levels and saturated fat in our diet. So, we'll have a look at what's driving that controversy and what the data actually says in this next video here.